Timothy A Yap, from the University of Texas MD Anderson Cancer Center, Houston, TX, US, discusses recent advances and challenges in precision cancer medicine, and how we can improve awareness and understanding of this important subject in the wider community.
1. What have been the most important advances in precision cancer medicine in the last year? (0:08)
2. What are the short- and long-term goals of precision medicine in oncology? (1:55)
3. How can we overcome the challenges of tumour heterogeneity and clonal evolution? (2:36)
4. How do you decide which trial to offer patients using precision medicine technologies? (3:46)
5. How can we improve public awareness and understanding of precision medicine? (4:41)
Speaker disclosures: Timothy A Yap has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Prostate Cancer
Axel Merseburger: International Men’s Day and EU Prostate Cancer Day and the Importance of Raising Awareness of Men’s Health and Well-being
Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), gives his thoughts on the importance of International Men’s Day and EU Prostate Cancer Day in raising awareness of men’s health and well-being. Question International Men’s Day and EU Prostate Cancer Day are both held in November. What is the importance of raising awareness of male […]
Axel S Merseburger, ESMO 2021: Highlights and Key Data in Advanced Prostate Cancer
touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]
Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study
touchONCOLOGY joins Professor Neeraj Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA) at ESMO 2021 to discuss the much-anticipated results of the COSMIC-021 study of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Questions 1. What is the rationale for the combined use of cabozantinib and atezolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!